Monalizumab: inhibiting the novel immune checkpoint NKG2A

Author(s):: Hall, T. van (0000-0002-9115-558X); Andre, P.; Horowitz, A.; Ruan, D.F.; Borst, L. (0000-0001-9433-3006); Zerbib, R.; Narni-Mancinelli, E.; Burg, S.H. van der (0000-0002-6556-0354); Vivier, E.

Published: 2019
Publication type: Article / Letter to editor

Cancer immunotherapyCD8 T cellsNK cellsNKG2AInhibitory immune receptorHLA-EQa-1

Date issued: 2019-10-17
Language: English
Is part of: Journal for ImmunoTherapy of Cancer (2019), No. 1
hdl: 1887/121311
doi: 10.1186/s40425-019-0761-3